1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19
20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35
36 | 37 | 38 | 39 | 40 | 41 | 42 | 43

Footnote 1:
Ricketts, Maura, et al, Emerging Infectious Diseases, Volume 3, Number 2, 1997. National Center for Infectious Diseases, CDC.

Footnote 2:
Division of Viral and Rickettsial Diseases, National Center for infectious Diseases, CDC.

Footnote 3:
Ibid.

Footnote 4:
Brown, P. The Human Spongiform Encephalopathies: Kuru, Creutzfeldt-Jakob Disease, and the Gerstmann-Straussler-Scheinker Syndrome. Current topics in microbiology and immunology, vol. 172. New York, 1991.

Footnote 5:
The gene is known as the scrapie amyloid precursor gene and is located on chromosome 20.

Footnote 6:
Brown, Paul, M.D. National Institute of Neurological Disorders and Strokes.

Footnote 7:
Manuelidis, L. The dimensions of Creutzfeldt-Jakob disease. Transfusion 1994; 34:915-28.

Footnote 8:
Sanders, et al. Dorland's Medical Dictionary, 28th edition, 1998.

Footnote 9:
Ozel, M. Small virus-like structure in fractions from scrapie hamster brain. Lancet 1994; 343:894-5.

Footnote 10:
Adams, R. D. et al. Principles of Neurology, 6th edition, 771-773.

Footnote 11:
De Silva, R. Human spongiform encephalopathy: clinical presentations and diagnostic tests. Methods in molecular medicine: prion diseases; 1996:15-33.

Footnote 12:
Masters, CL et al; Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familiar and sporadic clustering. Ann Neurol 1979; 5: 177-88.

Footnote 13:
Holman, R. Creutzfeldt-Jakob Disease in the United States, 1979-1994: Emerging Infectious Diseases, Vol 2, Number 4, 1996.

Footnote 14:
Campbell, D. et al. CJD Fact Sheet, CJD Voice.

Footnote 15:
Ibid.

Footnote 16:
Gibbs, C.J. National Institutes of Health.

Footnote 17:
Collinge, J. et al. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991; 337:1441-1442.

Footnote 18:
Lasmezas, C.I.; et al. Transmission of the BSE agent in mice in the absence of abnormal prion protein. Science 1997; 275:402-5.

Footnote 19:
Will, R.G. et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.

Footnote 20:
Gibbs, C.J. et al. Creutzfeldt-Jakob disease: transmission to the chimpanzee. Science 1968; 161: 388-91.

Footnote 21:
Brown, P. Environmental causes of human spongiform encephalopathy. Methods in molecular medicine: prion diseases. Humana Press; 1996: 139-54.

Footnote 22:
Esmonde, T. et al. Creutzfeldt-Jakob disease and lyophilised dura mater grafts. Journal of Neurol Neuosurg Psychiat. 1994; 56:999-1000.

Footnote 23:
Centers for Disease Control. Morb Moral Wkly Rep. 1985; 34:359-60, 365-6.

Footnote 24:
Nevin, S. et al. Subacute spongiform encephalopathy: a subacute form attributable to vascular dysfunction. Brain 1960; 83: 519-64.

Footnote 25:
National Institutes of Health, Biomedical Laboratory Safety, Section VII, Viral Agents.

Footnote 26:
Manuelidis, E.E., et al. Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet 1985; 2: 896-7.

Footnote 27:
Lavelle, G.C. et al. Isolation from mouse spleen of cell populations with high specific infectivity from scrapie virus. Infect Immun 1972; 5:319-23.

Footnote 28:
Heye, N. et al. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1994; 343: 298-99.

Footnote 29:
Creange A. et al. Creutzfeldt-Jakob disease after liver transplantation. Ann Neurol 1995; 38:269-72.

Footnote 30:
Patry, D. Neurology, 1998, June. Dept. of Medicine, University of Calgary.

Footnote 31:
Minutes of the Special Emphasis panel on Creutzfeldt-Jakob Disease and Blood Transfusion. Sept 24-25,1997.

Footnote 32:
Ricketts, Maura, et al, Emerging Infectious Diseases, Volume 3, Number 2, 1997. National Center for Infectious Diseases, CDC.

Footnote 33:
National Institutes of Health, Biomedical Laboratory Safety, Section VII, Viral Agents.

Footnote 34:
Brown, P. Guidelines for High Risk Autopsy Cases: Special Precautions for Creutzfeldt-Jakob Disease. College of American Pathologists, Autopsy Performance and Reporting, 1990.

Footnote 35:
Ibid.

Footnote 36:
Adams, R. D. et al. Principles of Neurology, 6th edition, 771-773.

Footnote 37:
Strub, C. G. and Frederick, L.G. The Principles and Practice of Embalming, 1967.

Footnote 38:
Guidelines for Control of Infections in Hospital Pathology, University of Washington Medical Center, 1998.

Footnote 39:
Dilution of bleach should be done at the time of use. Bleach diluted with water loses its effectiveness within hours of being diluted. Maximum effectiveness of bleach takes at least 10-30 minutes of contact. In the case of CJD, 2 hours of soaking is recommended.

Footnote 40:
National Institutes of Health, Biomedical Laboratory Safety, Section VII, Viral Agents.

Footnote 41:
Gilligan, T. Scott, ADA vs CJD, The Director, 2000.

Footnote 42:
National Center for Infectious Diseases, Hospital Infections Program. Creutzfeldt-Jakob Disease:Epidemiology, Risk Factors and Decontamination.

Footnote 43:
Will, R.G. Professor, National CJD Surveillance Unit, West General Hospital, Edinburgh. 2000.

© Copyright 2000, Management Associates, All Rights Reserved

Next